High Triglycerides News and Research

RSS

Study: Omega-3 fatty acids appear to protect heart function among heart attack survivors

Taking omega-3 fatty acids appeared to lower inflammation and guard against further declines in heart function among recent heart attack survivors already receiving optimal standard care, according to results from a randomized, controlled trial to be presented at the American College of Cardiology's 64th Annual Scientific Session in San Diego.

5 Mar 2015

Isis Pharmaceuticals announces positive results from Phase 1 study of ISIS-PKK Rx for HAE treatment

Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95 percent in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE).

24 Feb 2015

Isis receives $5 million from Biogen Idec to develop drugs for neurological disorders

Isis Pharmaceuticals, Inc. announced today it has earned a $5 million milestone payment from Biogen Idec associated with the validation of an undisclosed target to treat a neurological disorder under its broad strategic collaboration with Biogen Idec to develop drugs to treat patients with neurological disorders.

10 Feb 2015

PE/GHTN linked to higher frequency of cardiovascular and metabolic abnormalities

In a study to be presented on Feb. 5 in an oral concurrent session at 2:45 p.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting™, in San Diego, researchers of the MFMU Network will present findings of long term cardiovascular and metabolic abnormalities five to ten years later in women with preeclampsia/gestational hypertension during pregnancy.

9 Feb 2015

Isis receives $10 million from Biogen Idec to begin IND-supporting studies of ISIS-BIIB4 Rx

Isis Pharmaceuticals, Inc. announced today that it has earned a $10 million milestone payment from Biogen Idec for initiating the investigational new drug (IND)-supporting studies of ISIS-BIIB4 Rx.

5 Feb 2015

Women’s risk factors for heart disease

Heart disease is often thought of as a health problem for men, but more and more women die of heart disease each year than men, and from any other disease including breast cancer.

4 Feb 2015

Isis announces top-line results from ISIS-PTP1B Rx Phase 2 study in type 2 diabetes patients

Isis Pharmaceuticals, Inc. announced today top-line results from a Phase 2 study of ISIS-PTP1B Rx in patients with type 2 diabetes. In the Phase 2 study patients treated with ISIS-PTP1B Rx achieved statistically significant reductions in body weight and hemoglobin A1c (HbA1c).

3 Feb 2015

Researchers pinpoint rare gene mutations that increase risk of heart attack early in life

A team of investigators from the Broad Institute, Massachusetts General Hospital and other leading biomedical research institutions has pinpointed rare mutations in a gene called APOA5 that increase a person's risk of having a heart attack early in life. These mutations disable the APOA5 gene and also raise the levels in the blood of triglyceride-rich lipoproteins, a type of fat.

11 Dec 2014

Isis Pharmaceuticals CEO honored with SCRIP Lifetime Achievement Award

Stanley T. Crooke, Ph.D., M.D., founder, CEO and chairman of the board of directors of Isis Pharmaceuticals, Inc., has been awarded the 2014 SCRIP Lifetime Achievement Award, one of the most prestigious of its kind in the pharmaceutical and biotechnology industries worldwide.

5 Dec 2014

Early brain imaging studies may help prevent vascular diseases

Future prevention and treatment strategies for vascular diseases may lie in the evaluation of early brain imaging tests long before heart attacks or strokes occur, according to a systematic review conducted by a team of cardiologists, neuroscientists, and psychiatrists from Icahn School of Medicine at Mount Sinai and published in the October issue of JACC Cardiovascular Imaging.

27 Oct 2014

GNS automated data analytics can predict future risk of metabolic syndrome in patients

Research published today in The American Journal of Managed Care demonstrates that analysis of patient records using state-of-the-art data analytics can predict future risk of metabolic syndrome.

28 Jun 2014

Researchers identify mutation in fat-storage gene that appears to increase risk for type 2 diabetes

Researchers at the University of Maryland School of Medicine have identified a mutation in a fat-storage gene that appears to increase the risk for type 2 diabetes and other metabolic disorders, according to a study published online today in the New England Journal of Medicine.

23 May 2014

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

AstraZeneca today announced the US Food and Drug Administration (FDA) approved EPANOVA (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500 mg/dL).

7 May 2014

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Isis Pharmaceuticals, Inc. today reported a pro forma net operating loss (NOL) of $22.6 million for the three months ended March 31, 2014 compared to pro forma operating income of $4.5 million for the same period in 2013.

6 May 2014

Isis Pharmaceuticals reports final data from ISIS-APOCIIIRx Phase 2 study in patients with FCS

Isis Pharmaceuticals, Inc. announced the final data from its Phase 2 study of ISIS-APOCIIIRx as a monotherapy in patients with familial chylomicronemia syndrome, or FCS.

2 May 2014

FDA issues final approval for Lupin's sNDA for Antara capsules

Pharma Major Lupin Limited announced today that it has received final approval for its supplemental New Drug Application for Antara (Fenofibrate) capsules, 30 mg & 90 mg strengths from the United States Food and Drug Administration.

23 Oct 2013

Men who didn't exercise more likely to have dysfunctional HDL

There's no question that high levels of good cholesterol-also known as high-density lipoprotein -seem to be protective against heart disease. Rather than depositing fat into the blood vessels the way the "bad" cholesterol (low-density lipoprotein does, HDL appears to carry cholesterol away from blood vessels to the liver. From there, the liver processes it for removal from the body.

13 Oct 2013

Study: Heart disease emerges as number one killer among Indians

Heart disease has emerged as the number one killer among Indians, according to a recent study by the Registrar General of India ( RGI) and the Indian Council of Medical Research (ICMR).

25 Jul 2013

Omthera submits Epanova NDA to FDA for treatment of severe hypertriglyceridemia

Omthera Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of Epanova™ for the treatment for patients with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500mg/dL).

9 Jul 2013

Gene switch off may increase risk of heart and blood vessel disease: Research

Risk of heart and blood vessel disease may increase when a particular gene is switched off, according to preliminary research presented at the American Heart Association's Emerging Science Series Webinar.

20 Jun 2013